Sickle cell disease (SCD) is a severe blood disorder affecting millions worldwide, particularly in regions like sub-Saharan Africa and India. This article explores the causes, prevalence, symptoms, diagnosis, treatment, and global efforts to combat this debilitating disease.
The LMP Capital and Income Fund (SCD) has consistently outperformed its benchmark and peer group, delivering strong returns over the years. Its portfolio composition is well-positioned for the current economic environment, with overweights in energy, real estate, and value-oriented stocks. While the current discount to NAV is near historical highs, SCD remains an attractive long-term investment. Its focus on MLPs and REITs sets it apart from peers who are more heavily allocated to tech stocks or high-yield fixed income vehicles. However, higher expenses and a potential impact on distributions in the short term warrant caution.
